Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Launched by IOMEDICO AG · Sep 15, 2023

Keywords

ClinConnect Summary

The RUBIN trial is focused on collecting important information about various blood cancers, including Chronic Lymphocytic Leukemia (CLL) and several types of lymphoma. The goal is to create a national registry in Germany that will help researchers understand these diseases better by documenting details about patients' conditions, treatments, and outcomes. This study also aims to gather patient feedback on their experiences and establish a biobank, which is a collection of biological samples that can be used for future research.

To take part in this study, individuals must be at least 18 years old and have a confirmed diagnosis of one of the specified blood cancers. Participants need to provide written consent to join the study. If you decide to participate, you’ll be asked to share your treatment journey and experiences, which can help improve care for future patients. It's important to note that this study is currently recruiting participants and welcomes individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Confirmed diagnosis of the respective NHL
• • If patient is alive: signed written informed consent
• • For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
• • For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
• Exclusion Criteria:
• • No systemic therapy for respective lymphoid malignancy.